21 CFR 314.630 – Postmarketing safety reporting
Current as of: 2024 | Check for updates
|
Other versions
Drug products approved under this subpart are subject to the postmarketing recordkeeping and safety reporting requirements applicable to all approved drug products, as provided in §§ 314.80 and 314.81.